Table 2.
Analyses of Prognostic Factors for Survival After PSM
| Factor | Overall Survival | |||
|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | |||
| HR (95% CI) | P | HR (95% CI) | P | |
| Sex (male/female) | 0.496(0.193–0.273) | 0.145 | ||
| Age (≥65/<65 years) | 1.337(0.72–2.484) | 0.357 | ||
| Child-Pugh class (A/B/C) | 0.481 | |||
| A | 1.000 | |||
| B | 1.281(0.694–2.365) | 0.429 | ||
| C | 2.088(0.498–8.756) | 0.314 | ||
| Number of tumors (≥2/<2) | 1.608(0.848–3.049) | 0.146 | ||
| Tumor diameter (≥5/<5 cm) | 1.466(0.775–2.774) | 0.239 | ||
| AFP (≥400/<400 ng/mL) | 2.435(1.307–4.537) | 0.005 | 2.046(1.068–3.918) | 0.031 |
| ALP (≥125/<125 U/L) | 3.248(1.755–6.014) | <0.001 | 2.579(1.341–4.96) | 0.005 |
| Platelet (<100,000/≥100,000/mL) | 1.546(0.829–2.883) | 0.171 | ||
| ALT (≥40/<40U/L) | 1.112(0.639–1.935) | 0.708 | ||
| Leukocyte (<4000/≥4000/mL) | 1.758(0.697–4.432) | 0.232 | ||
| HBV (positive/negative) | 1.913(0.974–3.758) | 0.06 | ||
| Portal vein invasion (yes/no) | 2.08(1.147–3.77) | 0.016 | 1.5(0.797–2.822) | 0.208 |
| BCLC | 0.065 | |||
| A | 1.000 | |||
| B | 1.245(0.175–8.883) | 0.827 | ||
| C | 4.298(1.025–18.014) | 0.046 | ||
| D | 6.979(0.959–50.804) | 0.055 | ||
| Lymph node metastasis (yes/no) | 1.335(0.765–2.329) | 0.31 | ||
| Extrahepatic metastases (yes/no) | 1.135(0.636–2.025) | 0.668 | ||
| Triple therapy (Yes/No) | 0.477(0.271–0.842) | 0.011 | 0.385(0.215–0.689) | 0.001 |
Abbreviations: PSM, propensity score matching; HR, hazard ratio; AFP, alpha fetoprotein; ALP, alkaline phosphatase; ALT, alanine transaminase; HBV, hepatitis B virus; BCLC, Barcelona ClinicLiver Cancer.